Marko Lucijanic

Zagreb, 10000, Croatia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 222 publications

Symptomatic Osteoarthritis May Be Associated with Higher Symptom Burden and Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Prospective Two-Centre Study.

Symptomatic Osteoarthritis May Be Associated with Higher Symptom Burden and Thrombotic Risk in Patients with Myeloproliferative Neoplasms: A Prospective Two-Centre Study.

Journal: Journal of clinical medicine
Published: June 09, 2026

Hemoglobin Trajectories on SGLT2 Inhibitor Therapy in Heart Failure: Anemia Marks Adverse Prognosis While Erythrocytosis Is Transient and Not Associated with Adverse Outcomes.

Hemoglobin Trajectories on SGLT2 Inhibitor Therapy in Heart Failure: Anemia Marks Adverse Prognosis While Erythrocytosis Is Transient and Not Associated with Adverse Outcomes.

Journal: Journal of clinical medicine
Published: June 02, 2026

Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment.

Hepatotoxicity Profile of Bortezomib-Containing Regimens for First-Line Multiple Myeloma Treatment.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 01, 2026

Comparative Value of the Novel Age-Agnostic DIPSS-R Versus the DIPSS for Prognostication in Myelofibrosis: A Multicenter Evaluation and Reclassification Study.

Comparative Value of the Novel Age-Agnostic DIPSS-R Versus the DIPSS for Prognostication in Myelofibrosis: A Multicenter Evaluation and Reclassification Study.

Journal: Cancers
Published: May 31, 2026

Editorial: Differential diagnosis of erythrocytosis and analysis of their clinical utility.

Editorial: Differential diagnosis of erythrocytosis and analysis of their clinical utility.

Journal: Frontiers in medicine
Published: November 09, 2025

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence.

Chronotherapy in Hematological Malignancies: Evaluating the Rationale and Evidence.

Journal: Pharmacology research & perspectives
Published: October 30, 2025

Prevalence of Chronic Obstructive Pulmonary Disease and Asthma in Polycythemia Vera and Essential Thrombocythemia and Its Prognostic Implications.

Prevalence of Chronic Obstructive Pulmonary Disease and Asthma in Polycythemia Vera and Essential Thrombocythemia and Its Prognostic Implications.

Journal: Journal of clinical medicine
Published: October 26, 2025

Can ropeginterferon SURPASS resistance in essential thrombocythaemia?

Can ropeginterferon SURPASS resistance in essential thrombocythaemia?

Journal: The Lancet. Haematology
Published: September 29, 2025

Melanonychia in polycythaemia vera patient treated with hydroxycarbamide.

Melanonychia in polycythaemia vera patient treated with hydroxycarbamide.

Journal: British journal of haematology
Published: September 15, 2025

Differentiating polycythemia vera from sodium-glucose cotransporter 2 inhibitor-associated polycythemia.

Differentiating polycythemia vera from sodium-glucose cotransporter 2 inhibitor-associated polycythemia.

Journal: Acta diabetologica
Published: August 14, 2025

Cutaneous Extramedullary Hematopoiesis in a Patient With Myelofibrosis.

Cutaneous Extramedullary Hematopoiesis in a Patient With Myelofibrosis.

Journal: American journal of hematology
Published: July 13, 2025

Preoperative polycythemia may be associated with inferior postoperative outcomes: a retrospective study.

Preoperative polycythemia may be associated with inferior postoperative outcomes: a retrospective study.

Journal: Croatian medical journal
Published: July 10, 2025
Showing 1-12 of 222

Last Updated: 09/26/2026